Patents Examined by Steven Pohnert
  • Patent number: 11905552
    Abstract: A digital biosensor for assaying a target nucleic acid and methods of using the biosensor for digitally detecting the target nucleic acid are disclosed wherein the biosensor includes a substrate having a substrate surface and at least two electrodes, a linker molecule having a first moiety conjugated to the substrate surface, a ribonucleoprotein (RNP) conjugated to a second moiety of the linker molecule, and a guide ribonucleic acid (gRNA) having a first sequence capable of binding to the inactive RNP and a second sequence capable of binding to the target nucleic acid.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: February 20, 2024
    Assignees: KECK GRADUATE INSTITUTE OF APPLIED LIFE SCIENCES, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kiana Aran, Tara deBoer, Irina Conboy
  • Patent number: 11840730
    Abstract: Aspects of the invention relates to methods and compositions that are useful to reduce bias and increase the reproducibility of multiplex analysis of genetic loci. In some configurations, predetermined preparative steps and/or nucleic acid sequence analysis techniques are used in multiplex analyses for a plurality of genetic loci in a plurality of samples.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: December 12, 2023
    Assignee: MOLECULAR LOOP BIOSCIENCES, INC.
    Inventors: Gregory Porreca, Uri Laserson
  • Patent number: 11834720
    Abstract: Described herein are novel SCCmec right extremity junction (MREJ) sequences for the detection and/or identification of methicillin-resistant Staphylococcus aureus (MRSA). Disclosed are methods and compositions based on DNA sequences for the specific detection of MREJ sequences designated types xi, xii, xiii, xiv, xv, xvi, xvii, xviii, xix, and xx for diagnostic purposes and/or epidemiological typing.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: December 5, 2023
    Assignee: GENEOHM SCIENCES, INC.
    Inventors: Ann Huletsky, Richard Giroux
  • Patent number: 11788141
    Abstract: The present invention relates to a method, in particular an in vitro method, for identifying CD56+ NK cells, comprising analyzing the methylation status of at least one CpG position in the mammalian gene region for mevalonate (diphospho) decarboxylase (MVD), wherein a demethylation or lack of methylation of said gene region is indicative for a CD56+ NK cell, when compared to a non-CD56+ NK cell. The analyses according to the invention can identify CD56+ NK cells on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood or immune cells. The present invention furthermore provides an improved method for quantifying CD56+ NK cells, in particular in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: October 17, 2023
    Assignee: Precision for Medicine GmbH
    Inventor: Sven Olek
  • Patent number: 11781178
    Abstract: Provided herein are compositions and methods for the synthesis, amplification, and in vitro transcription of full-length cDNA, or cDNA fragments. Methods are provided for reverse transcription of RNA and amplification for in vitro transcription. Further provided are method for loading of dendritic cells with the RNA and homologous lysate for immune stimulation.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: October 10, 2023
    Assignee: Baylor College of Medicine
    Inventors: William K. Decker, Vanaja Konduri
  • Patent number: 11781127
    Abstract: The present invention provides a method for the isolation of sperm DNA from swabs taken from rape victims without having to perform a change in buffers. Non-sperm cells from the victim are digested with an enzyme and solubilized, and then in the same buffer an enzyme capable of digesting soluble DNA is added and the victim's DNA is degraded, leaving only the rapist's DNA intact. Since no change of buffer is needed, no centrifugation or filtration steps are needed. The inventive method has utility particularly in the forensic science field.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: October 10, 2023
    Inventor: Alex Garvin
  • Patent number: 11773458
    Abstract: Methods for the rapid detection of the presence or absence of BK virus in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting BK virus and kits are provided that are designed for the detection of BK virus.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: October 3, 2023
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Rochak Mehta, Jingtao Sun
  • Patent number: 11761041
    Abstract: The present invention relates to a method, in particular an in vitro method, for identifying monocytes, comprising analyzing the methylation status of at least one CpG position in the mammalian gene region for parkin RBR E3 ubiquitin protein ligase (PARK2), wherein a de-methylation or lack of methylation of said gene region is indicative for a monocyte, when compared to a non-monocyte cell. The analyses according to the invention can identify monocytes on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood or immune cells. The present invention furthermore provides an improved method for quantifying monocytes, in particular in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue. Also claimed are kits and specific oligonucleotides for use as primers or probes.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: September 19, 2023
    Assignee: Precision for Medicine GmbH
    Inventor: Sven Olek
  • Patent number: 11725243
    Abstract: The present invention relates to a method, in particular an in vitro method, for identifying follicular helper T cells, comprising analyzing the methylation status of at least one CpG position in the mammalian gene region for leukemia inhibitory factor (LIF), wherein a demethylation of said gene region is indicative for a follicular helper T cell, when compared to a non-follicular helper T cell. The analyses according to the invention can identify follicular helper T cells on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood cells. The present invention furthermore provides an improved method for quantifying follicular helper T cells in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: August 15, 2023
    Assignee: Precision for Medicine GmbH
    Inventors: Sven Olek, Ulrich Hoffmüller
  • Patent number: 11697842
    Abstract: Provided herein are compositions and methods for the synthesis, amplification, and in vitro transcription of full-length cDNA, or cDNA fragments. Methods are provided for reverse transcription of RNA and amplification for in vitro transcription. Further provided are method for loading of dendritic cells with the RNA and homologous lysate for immune stimulation.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: July 11, 2023
    Assignee: Baylor College of Medicine
    Inventors: William K. Decker, Vanaja Konduri
  • Patent number: 11680295
    Abstract: Disclosed are arrays of nucleic acid molecules, kits, methods of genotyping and marker assisted bovine breeding methods using SNPs on genes of the bovine interferon tau signaling pathway for improved bovine fertilization rate, or embryo survival, or both.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: June 20, 2023
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Hasan Khatib
  • Patent number: 11643687
    Abstract: The present invention relates to a method, in particular an in vitro method, for identifying B cells, comprising analyzing the methylation status of at least one CpG position in the mammalian gene region for Low density lipoprotein receptor-related protein 5 (LRP5), wherein a demethylation or lack of methylation of said gene region is indicative for a B cell, when compared to a non-B cell. The analyses according to the invention can identify B cells on an epi-genetic level and distinguish them from all other cells in complex samples, such as, for example, other blood or immune cells. The present invention furthermore provides an improved method for quantifying B cells, in particular in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue. Further claimed are kits and specific primers and probes for identifying methylation.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: May 9, 2023
    Assignee: Precision for Medicine GmbH
    Inventor: Sven Olek
  • Patent number: 11634747
    Abstract: A method for preserving and processing fetal nucleic acids located within maternal plasma is disclosed, wherein a sample of maternal blood containing fetal nucleic acids is treated to reduce both cell lysis of the maternal blood cells and deoxyribonuclease (DNase) and ribonuclease (RNase) activity within the fetal nucleic acids. The treatment of the sample aids in increasing the amount of fetal nucleic acids that can be identified and tested while maintaining the structure and integrity of the fetal nucleic acids.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: April 25, 2023
    Assignee: STRECK LLC
    Inventors: M. Rohan Fernando, Kate Chao-Wei Chen
  • Patent number: 11519042
    Abstract: The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of lung cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, a method for use of said nucleic acid sequences, which have been isolated, as a molecular marker or molecular markers, and a kit including at least one binding partner specific for at least one of the expression products of the HERV nucleic acid sequences.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: December 6, 2022
    Assignee: BIOMERIEUX
    Inventors: Philippe Perot, François Mallet, Cécile Montgiraud, Nathalie Mugnier
  • Patent number: 11479813
    Abstract: This application provides methods, kits, probes and primers, that can be used to analyze environmental samples, such as water samples, soil samples, and air samples. The methods and kits can include positive controls, to provide confidence in test results.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: October 25, 2022
    Assignee: UVic Industry Partnerships Inc.
    Inventors: Caren Christiane Helbing, Nicholas Veldhoen
  • Patent number: 11473147
    Abstract: The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of testicular cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, which have been isolated, as a molecular marker or molecular markers, and a kit including at least one binding partner specific for at least one of the expression products of the HERV nucleic acid sequences.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: October 18, 2022
    Assignee: BIOMERIEUX
    Inventors: Philippe Perot, François Mallet, Nathalie Mugnier
  • Patent number: 11459605
    Abstract: The present invention relates to a method for the in vitro diagnosis or prognosis of prostate cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit comprising at least one specific binding partner of at least one of the expression products of the HERV nucleic acid sequences.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: October 4, 2022
    Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYON
    Inventors: François Mallet, Nathalie Mugnier, Philippe Perot
  • Patent number: 11453920
    Abstract: The present invention relates to a method for the in vitro diagnosis or prognosis of ovarian cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit including at least one specific binding partner of at least one of the expression products of the HERV nucleic acid sequences.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: September 27, 2022
    Assignee: BIOMERIEUX
    Inventors: Philippe Perot, François Mallet, Nathalie Mugnier
  • Patent number: 11453916
    Abstract: The present invention relates to a method for in vitro diagnosis or prognosis of colon cancer, including a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said isolated nucleic acid sequences as a molecular marker/molecular markers, and a kit including at least one specific binding partner for at least one expression product of the HERV nucleic acid sequences.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: September 27, 2022
    Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYON
    Inventors: François Mallet, Nathalie Mugnier, Philippe Perot
  • Patent number: 11421276
    Abstract: This invention provides methods and compositions for diagnosing ischemia, ischemia reference expression profiles, and methods for identifying compounds for treating or preventing ischemia.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: August 23, 2022
    Assignee: The Regents of the University of California
    Inventors: Huichun Xu, Frank R. Sharp